ADSTILADRIN® (nadofaragene firadenovec-vncg) logo

This site is intended for US healthcare professionals.

Request a Rep
ADSTILADRIN® (nadofaragene firadenovec-vncg) logo
Request a Rep
Toggle navigation menu.

MECHANISM OF ACTION

ADSTILADRIN Offers a Unique Way
to Treat NMIBC as a Monotherapy

ADSTILADRIN is a non-replicating adenoviral vector–based gene-mediated immunotherapy

ADSTILADRIN delivers the IFNa2b gene to bladder urothelial cells 1

ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector that delivers the human interferon alpha 2B (IFNα2b) gene to bladder urothelial cells.1

ADSTILADRIN travels to cell nucleus to deliver the INFa2b gene 2

Once inside the bladder, ADSTILADRIN penetrates the bladder urothelial cells and travels to the cell nucleus to deliver the IFNα2b gene.1

Cells in the bladder that have taken up ADSTILADRIN begin to produce IFNa2b 3

Both normal urothelial and tumor cells in the bladder that have taken up ADSTILADRIN begin to produce and secrete high and transient local expression of IFNα2b, a naturally occurring cytokine.1,2

IFNα2b has antitumor activity and enhances the body’s
natural ability to fight cancer1,2

Watch video

ADSTILADRIN Is a Localized Treatment for Localized Tumors

ADSTILADRIN is a non-replicating, vector-based gene therapy that works with the patient’s own immune system to fight bladder cancer. It delivers the IFNα2b gene to bladder urothelial cells. It does not alter any existing genes in the body like some other gene therapies.1

The bladder is an ideal organ for gene therapy

Key reasons the bladder is ideal for this type of therapy:

  • Direct contact between the gene vector and tumor cells3,4
  • Local administration limiting systemic exposure4
  • Easy access to monitor effects of therapy5

Gene therapy helps fight cancer by:

  • Bolstering an immune response5,6
  • Protecting healthy cells from the side effects of these treatments5

Abbreviation: NMIBC, non–muscle-invasive bladder cancer.

Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)

Form Toggle

Your Information

Your Mailing Address

By providing the information requested, I am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-844-NADONOW (1-844-623-6669), Monday through Friday, 9 AM to 6 PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.(Required)
*Required field.

References: 1. ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; 2023. 2. Medrano RFV, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249-71284. doi:10.18632/oncotarget.19531 3. Narayan VM, Dinney CPN. Intravesical gene therapy. Urol Clin North Am. 2020;47(1):93-101. doi:10.1016/j.ucl.2019.09.011 4. Mahendran R, Tham SM, Esuvaranathan K. Gene therapy in urology. InTech. 2011. doi:10.5772/22235 5. Amer MH. Gene therapy for cancer: present status and future perspective. Mol Cell Ther. 2014;2:27. doi:10.1186/2052-8426-2-27 6. Das SK, Menezes ME, Bhatia S, et al. Gene therapies for cancer: strategies, challenges and successes. J Cell Physiol. 2015;230(2):259-271. doi:10.1002/jcp.24791

Important Safety Information

INDICATION

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.

WARNINGS AND PRECAUTIONS:

  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?

Yes No
Latest Updates

ADSTILADRIN ASP UPDATE

Effective April 1, 2024, ADSTILADRIN has established an average sales price (ASP) in accordance with the guidelines set forth by the Centers for Medicare & Medicaid Services Part B. This determination is a significant milestone for Ferring Uro-Oncology and represents our commitment to providing transparency and value to our customers.

To get ongoing updates about ADSTILADRIN, please sign up here.